ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
20.41
-0.22 (-1.07%)
At close: May 23, 2025, 4:00 PM
20.40
-0.01 (-0.05%)
After-hours: May 23, 2025, 4:02 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for ArriVent BioPharma stock ranges from a low of $36 to a high of $45. The average analyst price target of $39.29 forecasts a 92.50% increase in the stock price over the next year.
Price Target: $39.29 (+92.50%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +95.98% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +95.98% | May 14, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +81.28% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +120.48% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +91.08% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
291.93M
from 178.96M
Increased by 63.13%
Revenue Next Year
n/a
from 291.93M
EPS This Year
-3.40
from -2.56
EPS Next Year
-3.55
from -3.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 44.7M | 129.5M | ||
| Avg | n/a | 13.3M | 75.8M | ||
| Low | n/a | n/a | 44.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 870.8% | ||
| Avg | - | - | 468.0% | ||
| Low | - | - | 234.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -1.78 | -0.42 | ||
| Avg | -3.40 | -3.55 | -2.03 | ||
| Low | -4.41 | -4.40 | -3.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.